Condition category
Circulatory System
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status

Plain English Summary

Background and study aims
Atrial fibrillation (AF) is a common heart condition, affecting millions of people worldwide. When a person is suffering from AF, the electrical signals that control the heartbeat fire chaotically, causing the heart to beat irregularly and often very fast (arrhythmia). Studies have shown that AF can increase a persons’ risk of stroke, particularly ischaemic stroke (a condition in which the arteries that supply the brain with oxygen (carotid arteries) become narrowed or blocked, causing severely reduced blood flow). Many recent studies have shown that even very early stages of AF, so called "atrial high rate episodes" (AHRE), are linked with an increased risk of stroke. A large portion of these patients also develop AF over time. Stroke prevention from patients with AF is usually done using vitamin K antagonists (VKAs). These are anti-clotting medications which prevent blood clots from forming by interfering with the action of vitamin K (which plays a key role in blood clotting). These bear the risk of bleeding events and need to be dose-adjusted for each individual depending on blood values taken repetitively. Non-vitamin K antagonist oral anticoagulants (NOACs) have been introduced into clinical practice in recent years as an alternative, appearing safer than VKAs and being administered in a fixed dose. The aim of this study is to find out whether long-term treatment with Edoxaban (a NOAC) is more effective than the current strategy of no oral anticoagulation treatment in AHRE patients who present with an additional risk factor for stroke but who do not have diagnosed AF.

Who can participate?
Adults aged 65 or over with an implanted pacemaker or defibrillator that can detect AHRE.

What does the study involve?
Participants are randomly allocated to one of two groups. Those in the first group are given 60mg Edoxaban tablets to take every day for 24 months (which can later be reduced to 30mg a day if appropriate). Participants are also given a placebo (dummy) tablet to take which looks the same as a 100mg aspirin tablet to take once a day for the same length of time. Those in the second group are given a placebo (dummy) tablet that looks the same as a 60mg Edoxaban tablet and are either given a 100mg aspirin tablet to take every day (if the doctor feels they could benefit from it) or a placebo (dummy) tablet to take which looks the same as a 100mg aspirin tablet to take every day for 24 months. All participants are monitored throughout the study in order to record the amount who have suffered from a stroke or have died.

What are the possible benefits and risks of participating?
There is not expected to be any direct benefits from taking part in the study. The risks involves with participating are expected to be low as edoxaban has a clinical licence for stroke prevention in patients with atrial fibrillation.

Where is the study run from?
The study is run from the Atrial Fibrillation Competence Network e . V. (Germany)

When is the study starting and how long is it expected to run for?
February 2016 to September 2019

Who is funding the study?
1. Daiichi Sankyo Europe GmbH (Germany)
2. German Centre for Cardiovascular Research (Germany)

Who is the main contact?
1. Dr Benjamin Blank (Public)
2. Professor Paulus Kirchof

Trial website

Contact information



Primary contact

Dr Benjamin Blank


Contact details

Technologieförderung Münster GmbH
Mendelstraße 11



Additional contact

Prof Paulus Kirchhof


Contact details

The University of Birmingham
Vincent Drive
B15 2TT
United Kingdom

Additional identifiers

EudraCT number

2015-003997-33 number


Protocol/serial number


Study information

Scientific title

NOn-vitamin K Antagonist Oral Anticoagulants in patients with atrial high rate episodes - An investigator-driven, prospective, randomised, double-blind, multi-centre trial initiated by the European Society of Cardiology and AFNET



Study hypothesis

The aim of the trial is to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy to prevent stroke, systemic embolism, or cardiovascular death in patients with AHRE and at least two stroke risk factors but without AF.

Ethics approval

Not provided at time of registration

Study design

Prospective randomised double-blind multi-centre trial

Primary study design


Secondary study design

Randomised parallel trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet.


Atrial High Rate Episodes


The investigational medicinal product is being tested is the Non-vitamin K antagonist oral anticoagulant edoxaban. The IMP used as a comparator is acetylsalicylic acid or placebo. The patients will randomly be assigned to the “NOAC” or to the comparator group.

NOAC group: Participants will receive anticoagulation therapy with edoxaban. Edoxaban will be used at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD or with a reduction of dose to 30 mg OD in patients.
In the “NOAC” group one edoxaban tablet plus one placebo tablet matching in colour, weight, form and size to ASA 100 mg will be administered per day irrespective of stratum according to indication for use of antiplatelet therapy. The use of edoxaban eliminates the necessity of parallel intake of ASA 100 mg in case of an indication for use of antiplatelet therapy.

Usual Care group: Participants will receive either acetylsalicylic acid (ASA) or no antithrombotic therapy depending on the indication for use of antiplatelet therapy (stratification at the time of randomisation). In the “Usual Care” group either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator. A documented change of indication for use of antiplatelet therapy in follow-up will lead to blinded exchange of double-dummy study drug according to actual indication.

Treatment is starting at baseline. Based on the sample size estimation, the expected mean follow-up time will be about 28 months per patient with a minimum follow-up time of 12 months and a maximum follow-up time of presumably 44 months until end of final visit after required number of endpoints has been reached. Every patient will be followed-up until global end of study. The exact duration of follow-up will be determined by the accrual of events (event-driven study).

Intervention type



Phase III/IV

Drug names

1. Edoxaban
2. ASA

Primary outcome measures

Time from randomisation to the first occurrence of stroke, systemic embolism, or cardiovascular death.

Secondary outcome measures

1. All cause death is determined at 24 months
2. Major bleeding event rate (according to the International Society on Thrombosis and Haemostasis (ISTH) definitions) is determined at 24 months
3. Quality of life assessed using the EQ-5D including its visual-analogue scale and the Karnofsky scale at baseline, 12 and 24 months
4. Patient satisfaction is measured using the modified EHRA score (36) and PACT-Q (43) at baseline, 12 and 24 months
5. Cost effectiveness and health resource utilisation is estimated using quantification of relevant events, interventions, nights spent in hospital and cardiovascular therapies is determined at 24 months
6. Patient autonomy is measured at baseline, 12 and 24 months
7. Cognitive function is measured using the Montreal Cognitive Assessment (MoCA) baseline, 12 and 24 months

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Implanted pacemaker or defibrillator with feature of detection of AHRE, implanted at least 2 months prior to randomisation
2. AHRE detection feature activated adequately according to "Suggestions for optimal programming of devices for adequate detection of AHRE"
3. AHRE (≥ 180 bpm atrial rate and ≥ 6 min duration) documented by the implanted device via its atrial lead and stored digitally. AHRE episodes detected in the first 2 months after implantation of a new device involving placement or repositioning of electrodes are not counted. AHRE episodes recorded in the first two months after a simple "box change" operation, i.e. exchange of a pacemaker or defibrillator device without exchange or repositioning of electrodes, are eligible.
4. Aged 65 years or over
5. In addition, at least one of the following cardiovascular conditions leading to a CHA2DS2VASc score of 2 or more:
5.1. Heart failure (clinically overt or LVEF < 45%)
5.2. Arterial hypertension (chronic treatment for hypertension, estimated need for continuous antihypertensive therapy or resting blood pressure > 145/90 mmHg)
5.3. Diabetes mellitus
5.4. Prior stroke or transient ischemic attack (TIA)
5.5. Vascular disease (peripheral, carotid/cerebral, or aortic plaques on transesophageal echocardio-gram [TEE])
6. Provision of signed informed consent

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Any disease that limits life expectancy to less than 1 year
2. Participation in another controlled clinical trial, either within the past two months or still ongoing
3. Previous participation in the present trial NOAH
4. Drug abuse or clinically manifest alcohol abuse. Exclusion criteria related to a cardiac condition
5. Any history of overt AF or atrial flutter
6. Indication for oral anticoagulation (e.g. deep venous thrombosis)
7. Contraindication for oral anticoagulation in general
8. Contraindication for edoxaban as stated in the current SmPC
9. Indication for long-term antiplatelet therapy other than acetylsalicylic acid, especially dual antiplatelet therapy (DAPT) with acetylsalicylic acid and one of the following agents: clopidogrel, prasugrel, or ticagrelor. Patients with a transient requirement for DAPT (e.g. after receiving a stent) will be eligible when the need for DAPT is no longer present
10. Acute coronary syndrome, coronary revascularisation (PCI or bypass surgery), or overt stroke within 30 days prior to randomisation
11. End stage renal disease (creatinine clearance (CrCl) < 15 ml/min as calculated by the Cockcroft-Gault method)

Recruitment start date


Recruitment end date



Countries of recruitment

Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom

Trial participating centre

Kompetenznetz Vorhofflimmern e. V.
Mendelstraße 11

Sponsor information


Kompetenznetz Vorhofflmmern e.V. (Atrial Fibrillation NETwork - AFNET)

Sponsor details

Mendelstraße 11

Sponsor type




Funder type


Funder name

Daiichi Sankyo Europe GmbH

Alternative name(s)

Funding Body Type

Funding Body Subtype


Funder name

German Centre for Cardiovascular Research (Deutsches Zentrum für Herz-Kreislauf-Forschung)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Planned publication of study results in a peer reviewed journal.

Intention to publish date


Participant level data


Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes